Lindsey Piegza, Stifel chief economist, joins 'Money Movers' to discuss Piegza's thoughts on Friday's jobs report, if the window for interest rate cuts is shut, and much more. Chiefs' Travis Kelce ...

On February 5, David Grossman from Stifel Nicolaus maintained a “Buy” rating on the stock with a price target of $290.00. IBM’s growth prospects and financial outlook have led to the buy ...

Stifel Nicolaus analyst Shlomo Rosenbaum maintained a Buy rating on CSG Systems International (CSGS – Research Report) today and set a price target of $66.00. The company’s shares closed ...

September 5—John Baugh, Managing Director with Stifel Nicolaus, and Kemp Harr discuss John's research into the LVT flooring business. Listen to the interiew to hear more about how it's impacting ...

Stifel Financial Corp. announced a cash dividend of $0.46 per share on its common stock, payable on March 17, 2025, to shareholders recorded by March 3, 2025. Additionally, the company declared ...

Swimming against the flow of advisors leaving wirehouses, a three-person team formerly managing $12 billion at Stifel has moved to Morgan Stanley. Ari Spar, Justin Bell and John Magovern have ...

Investing.com -- Stifel upgraded Portillo's Inc (NASDAQ:PTLO) to Buy from Hold on company’s renewed focus on addressing traffic challenges and its potential for improved performance. Brokerage ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Stifel Financial (SF) CEO Ron Kruszewski sits down with Yahoo Finance Executive Editor Brian Sozzi in Davos, Switzerland, at the 2025 World Economic Forum to discuss his market (^DJI,^GSPC, ^IXIC ...

Stifel raised the firm’s price target on New Fortress Energy (NFE) to $23 from $17 and keeps a Buy rating on the shares. The firm notes that on Wednesday, New Fortress announced the 20-year ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...